Amgen Research (Munich) GmbH
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Clinical Trials
27
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Amgen Research (Munich) GmbH
- Target Recruit Count
- 25
- Registration Number
- NCT01741792
- Locations
- 🇩🇪
Universitätsmedizin, Göttingen, Germany
🇩🇪Universitätsklinikum des Saarlandes, Homburg, Germany
🇩🇪Universitätsklinikum Schleswig Holstein, Kiel, Germany
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Amgen Research (Munich) GmbH
- Target Recruit Count
- 93
- Registration Number
- NCT01471782
- Locations
- 🇺🇸
Children's Hospital Denver, Aurora, Colorado, United States
🇺🇸Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States
🇺🇸Washington University, ST. Louis, Missouri, United States
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Acute Lymphoblastic Leukemia
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Amgen Research (Munich) GmbH
- Target Recruit Count
- 225
- Registration Number
- NCT01466179
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
- Conditions
- B-ALL
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Amgen Research (Munich) GmbH
- Target Recruit Count
- 36
- Registration Number
- NCT01209286
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2010-09-22
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Amgen Research (Munich) GmbH
- Target Recruit Count
- 116
- Registration Number
- NCT01207388
- Locations
- 🇦🇹
1102 - LKH Graz, Graz, Austria
🇦🇹1107 - Krankenhaus der Elisabethinen, Linz, Austria
🇦🇹1106, Salzburg, Austria
- Prev
- 1
- 2
- Next